Unknown

Dataset Information

Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study.


ABSTRACT:

Objectives

This study examines the characteristics of studies that Health Canada uses to grant full marketing authorisation for products given a conditional approval between 1 January 1998 and 30 June 2017.

Design

Cohort study.

Data sources

Journal articles listing drugs that fulfilled their conditions and received full marketing authorisation, Notice of Compliance database, Notice of Compliance with conditions website, Qualifying Notices listing required confirmatory studies, clinicaltrials.gov, PubMed, Embase, companies making products being analysed, journal articles resulting from confirmatory studies.

Interventions

None.

Primary and secondary outcome measures

Characteristics of studies-study design (randomised controlled trials, observational), prim

SUBMITTER: Lexchin J 

PROVIDER: S-EPMC5931291 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature